emjreviews.com3d
FDA greenlights UCB’s IL-17 inhibitor for HS
The novel IL-17A and IL-17F inhibitor has been approved for moderate to severe hidradenitis suppurativa, a chronic and ...
FDA Approves UCB's Psoriasis Drug For Expanded Use In Painful Inflammatory Skin Disease
FDA approves UCB's Bimzelx for adults with moderate to severe hidradenitis suppurativa, supported by Phase 3 trials showing significant symptom improvement.
The American Journal of Managed Care4d
FDA Approves Bimekizumab in Hidradenitis Suppurativa
This approval is the fifth overall for bimekizumab (Bimzelyx; UCB Pharma) in the US, and they all have come in the last 13 ...
FiercePharma4d
Rapid growth spurt for UCB's Bimzelx continues with hidradenitis suppurativa nod marking 5th FDA approval
It was only last October that UCB’s up-and-coming immunology powerhouse Bimzelx first crossed the FDA finish line in ...
BioWorld4d
UCB chalks hidradenitis suppurativa as fifth indication for Bimzelx
The U.S. FDA added hidradenitis suppurativa to the label for UCB SA’s Bimzelx (bimekizumab-bkzx), throwing renewed light on the indication, a chronic disease that causes painful, boil-like lumps that ...
FiercePharma6d
Eisai sunsets development, access program for withdrawn obesity med in Dravet syndrome
UCB bangs drum for epilepsy drug in videos about ‘sound of profound’ seizure reduction Lorcaserin, which was developed by ...
UCB SA (0NZT) Receives a Buy from Barclays
In a report released today, Charles Pitman CFA from Barclays maintained a Buy rating on UCB SA (0NZT – Research Report), with a price target of ...